MPM Cross-Border Collaboration and Clinical Strategy Forum in Shanghai on April 27, 2026 — Fully Booked

Prior to joining MPM BioImpact, Frank served as Senior Vice President and Global Head of Clinical Development at Kite, a Gilead Company. Previously Frank held positions as Chief Medical Officer at Verastem, Inc. (also known as Verastem Oncology) and Vice President, Head of Oncology Clinical Research at bluebird bio. In addition, he was clinical development head of global cell therapy approaches at Takeda Pharmaceuticals, where he also held various leadership roles of increasing prominence including global clinical lead and medical team lead for two distinct cancer therapies. Earlier in his career, Frank was a member of the oncology medical teams at AstraZeneca and Sanofi-Aventis.

Board certified in Hematology/Oncology, Internal Medicine and Palliative Care Medicine, Frank was a research scholar at the University of Texas MD Anderson Cancer Center and is currently an assistant professor at the Heinrich Heine University in Düsseldorf, Germany, where he received his M.D. He earned his Ph.D. from the Rheinische-Friedrich-Wilhelm University in Bonn, Germany.

Haotian Wang is a graduate of Tsinghua University/PUMC. He has 10+ years of clinical medicine experience, and 8+ years clinical development, management and investment experience in healthcare industry. 

As a founding team member of top tier China CRO and the core team member, he has supported 70+ IND submissions with successful approval (US/China), 150+ Phase I/IIa trials, 50+ Phase II/III studies, and 4 NDA/BLA approvals. He joined Legend Capital in 2021, served as a VP and director, focusing on early-stage biotech investment. Successively participated and worked as a core team member in the investment 10+ projects with a cumulative investment amount of about 100M USD, and providing post-investment support for 20+ projects, covering R&D translation and strategic planning. 

He has hands-on experience in founding medical startups and CROs, with expertise in US/China regulatory systems and cross-cultural collaboration.

Dr. Jin Wang is Vice President of Clinical Development at K2 Therapeutics, where she leads global development strategies and supports investment, search and evaluation, and business development initiatives. With 15 years of drug development experience, Dr. Wang has directed programs spanning early to late phases, including globally approved Tislelizumab and Zanidatamab.

Before joining K2, Dr. Wang held senior leadership roles across global biopharma. At Gilead Sciences, she led clinical development for the APAC region. As Chief Medical Officer at Ablaze Pharmaceuticals, she advanced a radiopharmaceutical pipeline to IND-enabling stages prior to its acquisition by Bristol Myers Squibb. At BeiGene, she directed global development strategies and cross-functional teams for major oncology assets.

Her earlier career includes impactful contributions at Eli Lilly and IQVIA, as well as hands-on patient care at Shanghai Changzheng Hospital.

Dr. Wang holds an MD and PhD in Medicine and is board-certified in Medical Oncology.

Dr. David Kolesky is a Principal at MPM BioImpact. He is responsible for driving investments and company creation activities.

Before joining MPM BioImpact, David was a Principal at Flagship Pioneering, where he focused on conceiving, creating, and operating new bioplatform technology companies. David co-founded and helped launch several companies, notably Senda Biosciences and Montai Health, where he held key leadership roles at early stages of development including Chief Scientific Officer and Chief Innovation Officer at Montai, and Head of Platform at Senda. David has developed a wide range of scientific and technical experience by working across diverse platforms, including AI-enabled small molecule discovery, programmable delivery of genomic medicines, and cell & tissue engineering. 

David received his Ph.D. in Engineering Sciences from Harvard University and conducted a postdoctoral fellowship at the Wyss Institute for Biologically Inspired Engineering. His work has been published in top journals and he is co-inventor of several issued patents. David has received numerous awards, including the National Inventor’s Hall of Fame Collegiate Inventor Prize.

A native of South Florida, David received his B.S in Materials Science and Engineering from the University of Florida.

Samit Hirawat, M.D., serves as an independent member of the Board of Directors at K2 Therapeutics. 

Most recently, Samit Hirawat, M.D., served as Chief Medical Officer, Executive Vice President, and Head of Global Drug Development at Bristol Myers Squibb, where he oversaw the drug development development portfolio and advanced multiple transformative therapies across therapeutic areas and modalities to registration trials and approvals globally. Prior to that, he spent more than a decade at Novartis Pharmaceuticals in roles of increasing strategic responsibility, leading to his position as Executive Vice President and Head of Oncology Development.  Earlier in his career, Samit held clinical development positions at PTC Therapeutics and Pharmacia/Pfizer.

Samit Hirawat, M.D., earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) from Sawai Man Singh Medical College in Jaipur, India. He completed his Internal Medicine residency and Medical Oncology fellowship at North Shore University Hospital. He has published more than 150 peer-reviewed manuscripts and abstracts across therapeutic areas. 

Dr. Ansbert Gadicke is the Managing Partner of MPM BioImpact. Ansbert founded MPM Capital in 1992 as a biotech venture capital firm and later its affiliate BioImpact Capital for private/public funds. He is the driving force at MPM BioImpact behind building leading companies such as BioMarin Pharmaceuticals (NASDAQ: BMRN), Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), TriNetX, and Pharmasset (acquired by Gilead Sciences) and, more recently, Cullinan Therapeutics (NASDAQ: CGEM), ElevateBio and Orna Therapeutics. MPM BioImpact believes that these companies, in which Ansbert was the lead investor and served on the Boards of Directors, are some of the biggest successes in biotech – companies that ultimately result in helping thousands of patients live longer and vastly improved lives. For example, Sovaldi, developed by Pharmasset, was the first cure for Hepatitis C, the most successful product launch in the pharmaceutical industry and has today cured over 6 million patients of Hepatitis. Prior to founding MPM, Ansbert was at The Boston Consulting Group in their Boston office.

Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM BioImpact. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert is a recipient of the 2017 Global Oncology Visionary Award. He is a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.

Ansbert received an M.D. from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.